[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,822,382
  • Shares Outstanding, K 179,565
  • Annual Sales, $ 1,272 M
  • Annual Income, $ -245,030 K
  • EBIT $ -269 M
  • EBITDA $ -162 M
  • 60-Month Beta 3.46
  • Price/Sales 8.70
  • Price/Cash Flow N/A
  • Price/Book 25.97

Options Overview Details

View History
  • Implied Volatility 77.86% (+0.19%)
  • Historical Volatility 76.25%
  • IV Percentile 68%
  • IV Rank 49.94%
  • IV High 95.11% on 10/10/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 5) 4.26 (7.07%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 26,964
  • Volume Avg (30-Day) 35,648
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 357,228
  • Open Int (30-Day) 365,963
  • Expected Range 56.01 to 64.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 4
  • High Estimate $-0.31
  • Low Estimate $-0.50
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) -13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.31 +33.02%
on 06/09/26
63.11 -4.50%
on 07/01/26
+10.65 (+21.46%)
since 06/02/26
3-Month
42.41 +42.11%
on 04/10/26
63.11 -4.50%
on 07/01/26
+12.88 (+27.18%)
since 04/02/26
52-Week
41.73 +44.43%
on 03/30/26
104.32 -42.23%
on 10/09/25
+1.09 (+1.84%)
since 07/02/25

Most Recent Stories

More News
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 42.91 (+0.68%)
AZN : 195.15 (+6.14%)
MRK : 129.56 (+3.34%)
GILD : 131.27 (+4.21%)
TEM : 60.27 (-2.16%)
GSK : 53.66 (+4.60%)
ARKK : 81.25 (-0.73%)
BMY : 58.13 (+4.16%)
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc....

TEM : 60.27 (-2.16%)
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software ...

TEM : 60.27 (-2.16%)
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

Research highlights how ExomeReveal RNA analysis resolves ambiguity around uncertain variants to enable more genetic disease diagnoses

TEM : 60.27 (-2.16%)
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare...

TEM : 60.27 (-2.16%)
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced...

TEM : 60.27 (-2.16%)
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH , a next-generation...

TEM : 60.27 (-2.16%)
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform...

TEM : 60.27 (-2.16%)
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs...

TEM : 60.27 (-2.16%)
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically...

TEM : 60.27 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 66.80
2nd Resistance Point 64.95
1st Resistance Point 62.61
Last Price 60.27
1st Support Level 58.42
2nd Support Level 56.57
3rd Support Level 54.23

See More

52-Week High 104.32
Fibonacci 61.8% 80.41
Fibonacci 50% 73.03
Fibonacci 38.2% 65.64
Last Price 60.27
52-Week Low 41.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.